Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
Phase 2 Completed
60 enrolled 9 charts
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Phase 2 Completed
34 enrolled 18 charts
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
Phase NA Completed
10 enrolled 11 charts
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
Phase 2 Completed
11 enrolled 12 charts
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
Phase 2 Completed
201 enrolled 12 charts
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Phase 3 Completed
744 enrolled
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Phase 3 Completed
657 enrolled 8 charts
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
68 enrolled 8 charts
BMT CTN 0903
Phase 2 Completed
20 enrolled 25 charts
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Phase 2 Completed
422 enrolled 19 charts
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 3 Completed
256 enrolled 13 charts
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Phase 2 Completed
11 enrolled
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Phase 2/3 Completed
361 enrolled 16 charts
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
Phase 2 Completed
24 enrolled 8 charts
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
Phase NA Completed
87 enrolled 10 charts
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase 3 Completed
233 enrolled 7 charts
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
Phase 2 Completed
125 enrolled
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Phase 2 Completed
6 enrolled 16 charts
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
Phase 1/2 Completed
47 enrolled 8 charts
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Phase 2 Completed
158 enrolled 10 charts
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Phase 2 Completed
60 enrolled 15 charts
Cord Blood Expansion on Mesenchymal Stem Cells
Phase 1 Completed
98 enrolled
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Phase 2 Completed
20 enrolled 11 charts
ALBUM
Phase 2 Completed
16 enrolled 7 charts
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
Phase 2 Completed
107 enrolled 12 charts
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
Phase 1/2 Completed
50 enrolled 10 charts
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
Phase 1/2 Completed
24 enrolled
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
Phase 2 Completed
142 enrolled 11 charts
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Phase 2 Completed
20 enrolled
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
Phase 2 Completed
120 enrolled 8 charts
Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Phase 2 Completed
45 enrolled 12 charts
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
Phase 2 Completed
200 enrolled
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Phase 2 Completed
8 enrolled 8 charts
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
7 enrolled
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Phase 2 Completed
35 enrolled 11 charts
Bu Flu TBI
Phase 1/2 Completed
147 enrolled 19 charts
LCCC0510
Phase 1/2 Completed
54 enrolled 17 charts
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Phase 2 Completed
48 enrolled 12 charts
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Phase 2 Completed
71 enrolled 12 charts
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Phase 1 Completed
33 enrolled
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
Phase 2 Completed
56 enrolled 10 charts
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Phase 2 Completed
82 enrolled
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
Phase 2 Completed
51 enrolled
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Phase 1 Completed
145 enrolled
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
Phase 2 Completed
2 enrolled
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
Phase 2 Completed
6 enrolled 3 charts
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Phase 2 Completed
96 enrolled 5 charts
Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Phase 2 Completed
263 enrolled